轻型卒中伴大血管闭塞:机械取栓与最佳药物治疗的国际多中心研究及荟萃分析
本研究回顾性汇总16中心5年内251例轻型 deficits 急诊大血管闭塞(mELVO)患者,比较机械取栓(MT)与最佳药物治疗(bMM),并荟萃分析4项研究843例患者。结果显示两组多数疗效与安全结局相似,但bMM的无症状颅内出血率更低,MT的3个月功能独立率更低;调整分析后MT与无症状颅内出血风险升高相关,荟萃分析中未调整的MT与症状性颅内出血风险升高相关,调整后不显著。结论认为两种治疗结局相似,但无法得出治疗效应结论,需随机临床试验解决临床不确定性。
要点
- 轻型卒中伴大血管闭塞患者中,机械取栓与最佳药物治疗的多数疗效和安全性结局相似。
- 最佳药物治疗的无症状颅内出血率低于机械取栓(4.6% vs 17.5%)。
- 机械取栓的3个月功能独立率低于最佳药物治疗(77.4% vs 88.5%)。
核心结论
- 多中心研究与荟萃分析提示,轻型卒中伴大血管闭塞患者接受机械取栓或最佳药物治疗的结局相似,但无法得出治疗效应结论。
- 临床不确定性需通过随机临床试验进一步解决。
研究设计与样本
- 回顾性汇总16个中心5年期间的251例轻型卒中伴大血管闭塞患者,其中机械取栓组138例,最佳药物治疗组113例。
- 同时进行荟萃分析,纳入4项报告机械取栓或最佳药物治疗疗效与安全结局的研究,共843例患者。
- 数据在2013年至2017年间分析。
主要发现
- 最佳药物治疗组无症状颅内出血率低于机械取栓组(4.6% vs 17.5%;P = .002)。
- 机械取栓组3个月功能独立率低于最佳药物治疗组(77.4% vs 88.5%;P = .02)。
- 两组在其他疗效或安全结局上无差异。
- 多变量分析中,机械取栓与无症状颅内出血风险升高相关(OR 11.07;95% CI 1.31-93.53;P = .03)。
- 荟萃分析未调整分析中,机械取栓与症状性颅内出血风险升高相关(OR 5.52;95% CI 1.91-15.49;P = .002;I2 = 0%),调整分析后不显著(OR 2.06;95% CI 0.49-8.63;P = .32;I2 = 0%)。
临床怎么用
- 对于轻型卒中伴大血管闭塞患者,机械取栓与最佳药物治疗的多数结局相似,临床决策需个体化并考虑出血风险。
- 机械取栓可能增加无症状颅内出血风险,应密切监测。
局限性
- 本研究为回顾性汇总分析,可能存在选择偏倚和混杂因素。
- 部分随访评估缺失,功能独立率分析采用了插补方法。
- 荟萃分析纳入研究数量有限,调整分析后样本量较小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The benefit of mechanical thrombectomy (MT) in patients with stroke presenting with mild deficits (National Institutes of Health Stroke Scale [NIHSS] score <6) owing to emergency large-vessel occlusion (ELVO) remains uncertain. OBJECTIVE: To assess the outcomes of patients with mild-deficits ELVO (mELVO) treated with MT vs best medical management (bMM). DATA SOURCES: We retrospectively pooled patients with mELVO during a 5-year period from 16 centers. A meta-analysis of studies reporting efficacy and safety outcomes with MT or bMM among patients with mELVO was also conducted. Data were analyzed between 2013 and 2017. STUDY SELECTION: We identified studies that enrolled patients with stroke (within 24 hours of symptom onset) with mELVO treated with MT or bMM. MAIN OUTCOMES AND MEASURES: Efficacy outcomes included 3-month favorable functional outcome and 3-month functional independence that were defined as modified Rankin Scale scores of 0 to 1 and 0 to 2, respectively. Safety outcomes included 3-month mortality and symptomatic and asymptomatic intracranial hemorrhage (ICH). RESULTS: We evaluated a total of 251 patients with mELVO who were treated with MT (n = 138; 65 women; mean age, 65.2 years; median NIHSS score, 4; interquartile range [IQR], 3-5) or bMM (n = 113; 51 women; mean age, 64.8; median NIHSS score, 3; interquartile range [IQR], 2-4). The rate of asymptomatic ICH was lower in bMM (4.6% vs 17.5%; P = .002), while the rate of 3-month FI (after imputation of missing follow-up evaluations) was lower in MT (77.4% vs 88.5%; P = .02). The 2 groups did not differ in any other efficacy or safety outcomes. In multivariable analyses, MT was associated with higher odds of asymptomatic ICH (odds ratio [OR], 11.07; 95% CI, 1.31-93.53; P = .03). In the meta-analysis of 4 studies (843 patients), MT was associated with higher odds of symptomatic ICH in unadjusted analyses (OR, 5.52; 95% CI, 1.91-15.49; P = .002; I2 = 0%). This association did not retain its significance in adjusted analyses including 2 studies (OR, 2.06; 95% CI, 0.49-8.63; P = .32; I2 = 0%). The meta-analysis did not document any other independent associations between treatment groups and safety or efficacy outcomes. CONCLUSIONS AND RELEVANCE: Our multicenter study coupled with the meta-analysis suggests similar outcomes of MT and bMM in patients with stroke with mELVO, but no conclusions about treatment effect can be made. The clinical equipoise can further be resolved by a randomized clinical trial.
引用
- Goyal N, Tsivgoulis G, Malhotra K, et al. Medical Management vs Mechanical Thrombectomy for Mild Strokes: An International Multicenter Study and Systematic Review and Meta-analysis. JAMA Neurol. 2020. PMID: 31545353. doi:10.1001/jamaneurol.2019.3112
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。